{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:03:39Z","timestamp":1792555419493,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novarti"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaad.2019.02.068","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T12:01:38Z","timestamp":1552305698000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":383,"title":["North American clinical management guidelines for hidradenitis suppurativa: A\u00a0publication from the United States and Canadian Hidradenitis Suppurativa Foundations"],"prefix":"10.1016","volume":"81","author":[{"given":"Ali","family":"Alikhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alhusayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Brassard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Hazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Jaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Orgill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Poulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib3","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.jaad.2015.07.026","article-title":"Pyrithione zinc as a general management strategy for hidradenitis suppurativa","volume":"73","author":"Danesh","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2230.2009.03377.x","article-title":"Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa","volume":"35","author":"Boer","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jaad.2009.07.048","article-title":"Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser","volume":"62","author":"Mahmoud","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib6","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2016.06.049","article-title":"Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series","volume":"75","author":"Riis","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa","volume":"76","author":"Fischer","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00325481.1970.11693572","article-title":"How I treat hidradenitis suppurativa","volume":"48","author":"Kipping","year":"1970","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ijd.13428","article-title":"Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients","volume":"56","author":"Armyra","year":"2017","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib10","article-title":"Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system","volume":"22","author":"Scheinfeld","year":"2016","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.det.2015.08.013","article-title":"Antibiotic treatment of hidradenitis suppurativa","volume":"34","author":"Bettoli","year":"2016","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients","volume":"28","author":"Bettoli","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"van der Zee","year":"2009","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Mendonca","year":"2006","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.02.068_bib16","first-page":"CD010081","article-title":"Interventions for hidradenitis suppurativa","author":"Ingram","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","article-title":"Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa","volume":"222","author":"Join-Lambert","year":"2011","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000329023","article-title":"Dapsone therapy for hidradenitis suppurativa: a series of 24 patients","volume":"222","author":"Yazdanyar","year":"2011","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09546630600830588","article-title":"Hidradenitis suppurativa treated with dapsone: a case series of five patients","volume":"17","author":"Kaur","year":"2006","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join-Lambert","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib21","article-title":"Extensive hidradenitis suppurativa (HS) Hurly stage III disease treated with intravenous (IV) linezolid and meropenem with rapid remission","volume":"21","author":"Scheinfeld","year":"2015","journal-title":"Dermatol Online J"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","article-title":"A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa","volume":"115","author":"Mortimer","year":"1986","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/7750.2007.00019","article-title":"Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy","volume":"11","author":"Kraft","year":"2007","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ajd.12362","article-title":"A case series of 20 women with hidradenitis suppurativa treated with spironolactone","volume":"56","author":"Lee","year":"2015","journal-title":"Australas J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.02.068_bib25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","article-title":"Metformin for the treatment of hidradenitis suppurativa: a little help along the way","volume":"27","author":"Verdolini","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib26","first-page":"44","article-title":"Finasteride in hidradenitis suppurativa: a \u201cmale\u201d therapy for a predominantly \u201cfemale\u201d disease","volume":"9","author":"Khandalavala","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0190-9622(99)70530-X","article-title":"Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa","volume":"40","author":"Boer","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0190-9622(84)70199-X","article-title":"Evaluation of isotretinoin treatment of hidradenitis suppurativa","volume":"11","author":"Dicken","year":"1984","journal-title":"J Am Acad Dermatol"},{"issue":"2-3","key":"10.1016\/j.jaad.2019.02.068_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000477207","article-title":"A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes","volume":"233","author":"Huang","year":"2017","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2230.1986.tb00512.x","article-title":"Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin","volume":"11","author":"Norris","year":"1986","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000315508","article-title":"Back and face involvement in hidradenitis suppurativa","volume":"221","author":"Poli","year":"2010","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000182261","article-title":"Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment","volume":"218","author":"Soria","year":"2009","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2010.10071.x","article-title":"Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?","volume":"164","author":"Boer","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjd.12884","article-title":"Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients","volume":"171","author":"Matusiak","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4103\/0019-5154.91821","article-title":"A study on the management of hidradenitis suppurativa with retinoids and surgical excision","volume":"56","author":"Puri","year":"2011","journal-title":"Indian J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1203475416659858","article-title":"Acitretin","volume":"21","author":"Tan","year":"2017","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib37","first-page":"155","article-title":"Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age","volume":"150","author":"Verdolini","year":"2015","journal-title":"G Ital Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2230.2002.11125.x","article-title":"Methotrexate is of limited value in the treatment of hidradenitis suppurativa","volume":"27","author":"Jemec","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjd.14086","article-title":"Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients","volume":"174","author":"Nazary","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000332846","article-title":"The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa","volume":"223","author":"van der Zee","year":"2011","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/09546634.2015.1088128","article-title":"Cyclosporine treatment of severe hidradenitis suppurativa--a case series","volume":"27","author":"Anderson","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archderm.1990.01670270071012","article-title":"Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis","volume":"126","author":"Gupta","year":"1990","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib43","first-page":"289P","article-title":"Cyclosporin-responsive hidradenitis suppurativa","volume":"88","author":"Buckley","year":"1995","journal-title":"J R Soc Med"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib44","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.jaad.2012.06.011","article-title":"Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A","volume":"67","author":"Bianchi","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.02.068_bib45","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/jdv.12765","article-title":"Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone","volume":"29","author":"Staub","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib46","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","article-title":"Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa","volume":"75","author":"Wong","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2230.2005.01983.x","article-title":"Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin","volume":"31","author":"Rose","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2019.02.068_bib48","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Annals Intern Med"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.02.068_bib51","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1365-4632.2010.04545.x","article-title":"A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa","volume":"49","author":"Amano","year":"2010","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2019.02.068_bib52","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1365-4632.2010.04638.x","article-title":"Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy","volume":"49","author":"Arenbergerova","year":"2010","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000365076","article-title":"Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature","volume":"229","author":"Bahillo Monn\u00e9","year":"2014","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib54","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archdermatol.2009.49","article-title":"Long-term successful adalimumab therapy in severe hidradenitis suppurativa","volume":"145","author":"Blanco","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5114\/reum.2016.64910","article-title":"Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab","volume":"54","author":"Bosni\u0107","year":"2016","journal-title":"Reumatologia"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib56","first-page":"291","article-title":"Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease","volume":"22","author":"Diamantova","year":"2014","journal-title":"Acta Dermatovenerol Croat"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000251217","article-title":"Successful treatment of recalcitrant hidradenitis suppurativa with adalimumab","volume":"1","author":"Gorovoy","year":"2009","journal-title":"Case Rep Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib58","first-page":"139","article-title":"Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab","volume":"7","author":"Harde","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ajg.2009.489","article-title":"A case of hidradenitis suppurativa refractory to anti-TNFalpha therapy in a patient with Crohn's disease","volume":"105","author":"Koilakou","year":"2010","journal-title":"Am J Gastroenteroly"},{"issue":"8","key":"10.1016\/j.jaad.2019.02.068_bib60","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00384-014-2110-9","article-title":"Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis","volume":"30","author":"Murphy","year":"2015","journal-title":"Int J Colorectal Dis"},{"issue":"8","key":"10.1016\/j.jaad.2019.02.068_bib61","first-page":"15","article-title":"Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab","volume":"16","author":"Reddick","year":"2010","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib62","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jaad.2014.10.002","article-title":"PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition","volume":"72","author":"Saraceno","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaad.2006.01.024","article-title":"Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab","volume":"55","author":"Scheinfeld","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl","key":"10.1016\/j.jaad.2019.02.068_bib64","first-page":"s15","article-title":"A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa","volume":"11","author":"Sotiriou","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/09546634.2011.571657","article-title":"Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa","volume":"23","author":"van Rappard","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib66","first-page":"181","article-title":"Hidradenitis suppurativa managed with adalimumab","volume":"8","author":"Yamauchi","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib67","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib68","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2011.10328.x","article-title":"New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab","volume":"165","author":"van Rappard","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib69","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2133.2008.08735.x","article-title":"Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?","volume":"159","author":"Brunasso","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib70","first-page":"169","article-title":"Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers","volume":"91","author":"Delage","year":"2011","journal-title":"Acta Dermatovenereol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib71","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2006.07.027","article-title":"Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients","volume":"56","author":"Fardet","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000102032","article-title":"Infliximab for the treatment of hidradenitis suppurativa","volume":"215","author":"Fernandez-Vozmediano","year":"2007","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1440-0960.2010.00623.x","article-title":"Hidradenitis suppurativa responding to treatment with infliximab","volume":"51","author":"Lasocki","year":"2010","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib74","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2133.2007.08332.x","article-title":"Long-term efficacy of a single course of infliximab in hidradenitis suppurativa","volume":"158","author":"Mekkes","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib75","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/09546634.2012.683767","article-title":"Long-term efficacy of infliximab in hidradenitis suppurativa","volume":"23","author":"Paradela","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib76","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0001-7310(07)70076-5","article-title":"[Hidradenitis suppurativa. Response to treatment with infliximab]","volume":"98","author":"Pedraz","year":"2007","journal-title":"Actas Dermosifiliograf"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib77","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2230.2006.02272.x","article-title":"Variable response of hidradenitis suppurativa to infliximab in four patients","volume":"32","author":"Usmani","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","article-title":"Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report","volume":"226","author":"van der Zee","year":"2013","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.02.068_bib81","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful treatment of severe hidradenitis suppurativa with anakinra","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib82","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjd.13292","article-title":"Two cases of severe hidradenitis suppurativa with failure of anakinra therapy","volume":"172","author":"Menis","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib83","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2019.02.068_bib84","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2019.02.068_bib85","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","article-title":"Ustekinumab for hidradenitis suppurativa: a case report","volume":"105","author":"Santos-Perez","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib86","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2340\/00015555-1229","article-title":"Management of recalcitrant hidradenitis suppurativa with ustekinumab","volume":"92","author":"Sharon","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib87","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib89","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1600-0625.2009.00967.x","article-title":"Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial","volume":"19","author":"Pelekanou","year":"2010","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib90","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib91","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib92","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2340\/00015555-0545","article-title":"Etanercept for the treatment of hidradenitis suppurativa","volume":"89","author":"Sotiriou","year":"2009","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2019.02.068_bib94","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.dld.2016.09.010","article-title":"Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab","volume":"48","author":"Tursi","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib95","first-page":"548","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"69","author":"Ebell","year":"2004","journal-title":"Am Fam Physician"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2019.02.068_bib96","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jaad.2015.07.048","article-title":"Local wound care and topical management of hidradenitis suppurativa","volume":"73","author":"Alavi","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib97","first-page":"216","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: can some factors influence the response to the treatment?","volume":"151","author":"Bettoli","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib98","first-page":"239","article-title":"The role of androgens and estrogens in hidradenitis suppurativa - a systematic review","volume":"24","author":"Riis","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2016.07.024","article-title":"Menses and pregnancy affect symptoms in hidradenitis suppurativa: a cross-sectional study","volume":"76","author":"Vossen","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib101","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bjd.12233","article-title":"Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support","volume":"168","author":"Danby","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.02.068_bib102","series-title":"Comprehensive Dermatologic Drug Therapy","author":"Wolverton","year":"2013"},{"issue":"1-3","key":"10.1016\/j.jaad.2019.02.068_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.08.047","article-title":"Pathogenesis and pharmacotherapy of hidradenitis suppurativa","volume":"672","author":"Nazary","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib104","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in\u00a0vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib105","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.02.068_bib106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12788\/j.sder.2017.017","article-title":"Pathophysiology of hidradenitis suppurativa","volume":"36","author":"Hoffman","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2019.02.068_bib107","series-title":"Humira (adalimumab) [package insert]","year":"2017"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib108","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2016.10.032","article-title":"Management of hidradenitis suppurativa in pregnancy","volume":"76","author":"Perng","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib109","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2019.02.068_bib110","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archderm.142.9.1110","article-title":"The cutting edge. Severe hidradenitis suppurativa treated with adalimumab","volume":"142","author":"Moul","year":"2006","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib111","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bjd.12713","article-title":"Four-weekly infliximab in the treatment of severe hidradenitis suppurativa","volume":"170","author":"Moriarty","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.jaad.2019.02.068_bib112","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jaad.2015.07.051","article-title":"Hidradenitis suppurativa in the pediatric population","volume":"73","author":"Liy-Wong","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.02.068_bib113","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2014.11.017","article-title":"Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement","volume":"72","author":"Deckers","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.02.068_bib114","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/bjd.13951","article-title":"Hidradenitis suppurativa-acne inversa: a relevant dermatosis in paediatric patients","volume":"173","author":"Bettoli","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2230.2001.00876.x","article-title":"Early-onset hidradenitis suppurativa","volume":"26","author":"Palmer","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.02.068_bib116","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40272-014-0091-3","article-title":"Hidradenitis suppurativa in children and adolescents: a review of treatment options","volume":"16","author":"Mikkelsen","year":"2014","journal-title":"Paediatr Drugs"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib117","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/archdermatol.2011.1950","article-title":"A systematic review of treatments for hidradenitis suppurativa","volume":"148","author":"Rambhatla","year":"2012","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.02.068_bib118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archderm.1952.01530200016002","article-title":"Pregnancy and apocrine gland diseases: hidradenitis, Fox-Fordyce disease","volume":"65","author":"Cornbleet","year":"1952","journal-title":"AMA Arch Derm Syphilol"},{"issue":"4","key":"10.1016\/j.jaad.2019.02.068_bib119","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13090","article-title":"Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study","volume":"171","author":"Kromann","year":"2014","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2019.02.068_bib120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jamadermatol.2014.430","article-title":"Cryoinsufflation for Hurley stage II hidradenitis suppurativa: a useful treatment option when systemic therapies should be avoided","volume":"150","author":"Pagliarello","year":"2014","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219303688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219303688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:49:25Z","timestamp":1759272565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219303688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0190962219303688"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.02.068","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"North American clinical management guidelines for hidradenitis suppurativa: A\u00a0publication from the United States and Canadian Hidradenitis Suppurativa Foundations","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.02.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}